Merrimack Pharmaceuticals, Inc. (MACK) |
| 15.145 0.015 (0.1%) 05-17 15:59 |
| Open: | 15.15 |
| High: | 15.165 |
| Low: | 15.14 |
| Volume: | 922,504 |
| Market Cap: | 224(M) |
| PE Ratio: | -168.28 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 15.89 |
| 52w Low: | 11.53 |
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Financials
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Company news
Thu, 23 May 2024
Robert C Gay Net Worth (2026) - GuruFocus
Fri, 10 May 2024
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock - Business Wire
Tue, 30 Apr 2024
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution - Business Wire
Wed, 27 Mar 2024
Merrimack Receives $225 Million Milestone Payment from Ipsen - Business Wire
Mon, 04 Mar 2024
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company - Yahoo Finance
Fri, 09 Feb 2024
Terns names Amy Burroughs CEO - BioCentury
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
